Boston Scientific Aktie 913577 / US1011371077
90.16
USD
-0.17
USD
-0.19%
20.11.2024
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Boston Scientific Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | Boston Scientific Corp. | 0.00 | 0.00 | USD |
| 2022 | Boston Scientific Corp. | 0.00 | 0.00 | USD |
| 2021 | Boston Scientific Corp. | 0.00 | 0.00 | USD |
| 2020 | Boston Scientific Corp. | 0.00 | 0.00 | USD |
| 2019 | Boston Scientific Corp. | 0.00 | 0.00 | USD |
| 2018 | Boston Scientific Corp. | 0.00 | 0.00 | USD |
| 2017 | Boston Scientific Corp. | 0.00 | 0.00 | USD |
| 2016 | Boston Scientific Corp. | 0.00 | 0.00 | USD |
| 2015 | Boston Scientific Corp. | 0.00 | 0.00 | USD |
| 2014 | Boston Scientific Corp. | 0.00 | 0.00 | USD |
Gewinn je Aktie- Boston Scientific
| 0.1 17 | 1.2 18 | 3.3 19 | -0.1 20 | 0.7 21 | 0.4 22 | 1.1 23 |
Umsatz je Aktie- Boston Scientific
| 6.5 17 | 7.0 18 | 7.6 19 | 7.0 20 | 8.3 21 | 8.8 22 | 9.7 23 |
KGV- Boston Scientific
| 332 17 | 29.7 18 | 13.6 19 | 61.8 21 | 104 22 | 53.9 23 |
Boston Scientific Corp.: Die Aktie (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 0.08 | 1.19 | 3.33 | -0.08 | 0.69 | 0.45 | 1.07 |
| Gewinn je Aktie unverwässert | 0.08 | 1.21 | 3.38 | -0.08 | 0.69 | 0.45 | 1.08 |
| Gewinn je Aktie verwässert | 0.07 | 1.19 | 3.33 | -0.08 | 0.69 | 0.45 | 1.07 |
| Dividende pro Aktie | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gesamtdividendenausschüttung in Mio. | 0.00 | 0.00 | 0.00 | 28.00 | 55.00 | 55.00 | 28.00 |
Boston Scientific Corp.: Unternehmenskennzahlen (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 6.50 | 7.01 | 7.61 | 7.00 | 8.29 | 8.81 | 9.73 |
| KGV (Jahresendkurs, EPS unverwässert) | 331.86 | 29.70 | 13.57 | - | 61.83 | 103.77 | 53.89 |
| KGV (Jahresendkurs, EPS verwässert) | 331.86 | 29.70 | 13.57 | - | 61.83 | 103.77 | 53.89 |
| KGV (Jahresendkurs) | 331.86 | 29.70 | 13.57 | - | 61.83 | 103.77 | 53.89 |
| Dividendenrendite Jahresende in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Eigenkapitalquote in % | 36.82 | 41.55 | 45.40 | 49.80 | 51.57 | 54.12 | 55.58 |
| Fremdkapitalquote in % | 63.18 | 58.45 | 54.60 | 50.20 | 48.43 | 45.88 | 44.42 |
Boston Scientific Corp.: GuV (in Mio. USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 9’048.00 | 9’823.00 | 10’735.00 | 9’913.00 | 11’888.00 | 12’682.00 | 14’240.00 |
| Umsatzveränderung in % | 7.89 | 8.57 | 9.28 | -7.66 | 19.92 | 6.68 | 12.29 |
| Bruttoergebnis vom Umsatz | 5’871.00 | 6’477.00 | 6’879.00 | 5’576.00 | 7’461.00 | 7’714.00 | 8’831.00 |
| Bruttoergebnisveränderung in % | 9.88 | 10.32 | 6.21 | -18.94 | 33.81 | 3.39 | 14.48 |
| Operatives Ergebnis | 1’525.00 | 1’737.00 | 1’712.00 | 601.00 | 1’922.00 | 1’824.00 | 2’181.00 |
| Veränderung Operatives Ergebnis in % | 23.38 | 13.90 | -1.44 | -64.89 | 219.80 | -5.10 | 19.57 |
| Ergebnis vor Steuern | 933.00 | 1’422.00 | 687.00 | -79.00 | 1’076.00 | 1’141.00 | 1’985.00 |
| Veränderung Ergebnis vor Steuern in % | 427.12 | 52.41 | -51.69 | - | - | 6.04 | 73.97 |
| Ergebnis nach Steuer | 104.00 | 1’671.00 | 4’700.00 | -82.00 | 1’040.00 | 698.00 | 1’593.00 |
| Veränderung Ergebnis nach Steuer in % | -70.03 | 1’506.73 | 181.27 | - | - | -32.88 | 128.22 |
Boston Scientific Corp.: Bilanz (in Mio. USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 12’030 | 12’273 | 16’688 | 15’450 | 15’607 | 14’896 | 15’606 |
| Langzeit Gesamtverbindlichk. pro Aktie | 4.64 | 5.07 | 8.48 | 8.31 | 7.95 | 7.74 | 7.28 |
| Eigenkapital | 7’012 | 8’726 | 13’877 | 15’327 | 16’622 | 17’573 | 19’530 |
| Veränderung Eigenkapital in % | 4.14 | 24.44 | 59.03 | 10.45 | 8.45 | 5.72 | 9.73 |
| Bilanzsumme | 19’042 | 20’999 | 30’565 | 30’777 | 32’229 | 32’469 | 35’136 |
| Veränderung Bilanzsumme in % | 5.23 | 10.28 | 45.55 | 0.69 | 4.72 | 0.74 | 8.21 |
Boston Scientific Corp.: Sonstige Angaben (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 0.08 | 1.21 | 3.38 | -0.08 | 0.69 | 0.45 | 1.08 |
| Veränderung Gewinn je Aktie (unverwässert) in % | -69.23 | 1’412.50 | 179.14 | -102.40 | - | -35.19 | 140.75 |
| Gewinn je Aktie (verwässert) | 0.07 | 1.19 | 3.33 | -0.08 | 0.69 | 0.45 | 1.07 |
| Veränderung Gewinn je Aktie (verwässert) in % | -70.12 | 1’493.04 | 179.99 | -102.44 | - | -35.09 | 140.59 |
| Anzahl Mitarbeiter | 29’000 | 32’000 | 36’000 | 38’000 | 41’000 | 45’000 | 48’000 |
| Veränderung Anzahl Mitarbeiter in % | 7.41 | 10.34 | 12.50 | 5.56 | 7.89 | 9.76 | 6.67 |
Boston Scientific Corp. Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Boston Scientific Corp. | Quartalszahlen | 29.01.2025 |
| Boston Scientific Corp. | Quartalszahlen | 23.04.2025 |
| Boston Scientific Corp. | Quartalszahlen | 23.07.2025 |
| Boston Scientific Corp. | Quartalszahlen | 22.10.2025 |
Boston Scientific Corp. vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2024 Earnings Release | 23.10.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 24.07.2024 |
| Hauptversammlung | Annual General Meeting | 02.05.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 24.04.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 31.01.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 26.10.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 27.07.2023 |
| Hauptversammlung | Annual General Meeting | 04.05.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 26.04.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 01.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 26.10.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 27.07.2022 |
| Hauptversammlung | Annual General Meeting | 05.05.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 27.04.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 02.02.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.58 |
| The Vanguard Group, Inc. | 8.52 |
| Vanguard Group, Inc. (Subfiler) | 8.47 |
| Fidelity Management & Research Co. LLC | 7.36 |
| State Street Corp. | 4.27 |
| Massachusetts Financial Services Co. | 3.88 |
| Vanguard Total Stock Market ETF | 3.17 |
| Vanguard 500 Index Fund | 2.62 |
| PRIMECAP Management Co. | 2.57 |
| BlackRock Fund Advisors | 2.49 |
| BlackRock Institutional Trust Co. NA | 2.22 |
| Wellington Management Co. LLP (Wellington Breakout) | 2.03 |
| Geode Capital Management LLC | 2.01 |
| Massachusetts Financial Services Co. | 1.74 |
| Vanguard PRIMECAP Fund | 1.74 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 36’000 | 38’000 | 41’000 | 45’000 | 48’000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.30 | 0.26 | 0.29 | 0.28 | 0.30 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 4’699 | 6’694 | 6’317 | 5’760 | 6’514 |
| Summe Anlagevermögen | 25’866 | 24’083 | 25’912 | 26’709 | 28’622 |
| Summe Aktiva | 30’565 | 30’777 | 32’229 | 32’469 | 35’136 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 10’351 | 9’614 | 9’525 | 9’282 | 9’492 |
| Summe Fremdkapital | 16’688 | 15’450 | 15’607 | 14’896 | 15’606 |
| Summe Eigenkapital | 13’877 | 15’327 | 16’622 | 17’573 | 19’530 |
| Summe Passiva | 30’565 | 30’777 | 32’229 | 32’469 | 35’136 |
Adresse
| 300 Boston Scientific Way, 01752-1234 Marlborough | |
| Telefon | +1 (508) 683-4000 |
| URL | http://www.bostonscientific.com |
Management
|
Arthur Crosswell Butcher
EVP, Group President-MedSurg & Asia Pacific |
|
Brenda Becker
Senior Vice President-Global Government Affairs |
|
Charles J. Dockendorff
Independent Director |
|
Charlie Attlan
SVP-New Business Development, Strategy & Portfolio |
|
Cheryl Pegus
Director |
|
Colin Morrison
Director-Business Development & Venture Capital |
|
Daniel J. Brennan
Chief Financial Officer & Executive Vice President |
|
David C. Habiger
Director |
|
David Scott Wichmann
Independent Director |
|
Edward J. Ludwig
Lead Independent Director |
|
Ellen M. Zane
Independent Director |
|
Emily Woodworth
Chief Accounting Officer, SVP & Group Controller |
|
Eric Francis Yves Thepaut
EVP, President-Europe, Middle East & Africa |
|
Jeffrey B. Mirviss
SVP & President-Peripheral Interventions |
|
Jessica L. Mega
Independent Director |
|
Jim Cassidy
Vice President & Franchise Lead-Pain Management |
|
Jodi Eddy
Chief Information & Digital Officer, Senior VP |
|
John Bradley Sorenson
Executive Vice President-Global Operations |
|
John Edward Sununu
Independent Director |
|
Jonathan Richard Monson
Senior Vice President-Investor Relations |
|
Joseph M. Fitzgerald
President-Interventional Cardiology & Executive VP |
|
June Chang
President-Greater China |
|
Kathryn Graves Unger
Vice President-Environmental, Social & Governance |
|
Kenneth Stein
Global Chief Medical Officer & Senior VP |
|
Lauren Tengler
Head-Investor Relations |
|
Mark Bickel
VP-Finance & Global Controller-Rhythm Management |
|
Mary Beth Moynihan
Chief Marketing Officer & Senior VP-Market Access |
|
Meghan M. Scanlon
SVP & President-Urology & Pelvic Health Division |
|
Michael F. Mahoney
Chairman, President & Chief Executive Officer |
|
Michael Jones
Senior Vice President & President-Endoscopy |
|
Milad Girgis
Vice President & Franchise Lead |
|
Rosaleen Burke
Senior Vice President-Global Quality & Regulatory |
|
Samuel Conaway
President-US Sales Cardiology Group |
|
Susan E. Morano
Independent Director |
|
Susan J. Thompson
Chief Corporate Counsel, VP & Assistant Secretary |
|
Vance Ronald Brown
Secretary, Senior Vice President & General Counsel |
|
Wendy Carruthers
Executive Vice President-Human Resources |
|
Yoshiaki Fujimori
Independent Director |